Surgery for Pancreatic Cancer With Oligo-Metastasis

N/ACompletedNCT04196816

University Hospital, Montpellier200 enrolled

Overview

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019). However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients. The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Pancreatic Cancer Pancreatic Surgery

Eligibility

Sex: ALLMin age: 18 YearsMax age: 95 Years

Medical Language ↔ Plain English

Inclusion criteria: \- Patients who had resection or destruction of one or more synchronous or metachronous metastases or local recurrence of pancreatic adenocarcinoma Details: * synchronous lesions, metachrones can be included * all distant lesions (hepatic, pulmonary) can be included * documented lymph node involvement after analysis of the specimen (hepatic hilum, mesenteric root, retroperitoneal or inter-aortic-cellar) can be included * patients with local recurrence who underwent surgical treatment Exclusion Criteria: \- Patient who reject the study protocol

Outcomes

Primary Outcomes

Overall survival

Overall survival at 3 years (percentage of patients alive). Overall survival (OS) (time from diagnosis until death, regardless of cause)

Time frame: 3 years

Secondary Outcomes

Progression-free survival

Progression-free survival (percentage of patients without recurrence) at 3 years. Progression-free survival (PFS) (time from diagnosis to time of first radiological evidence of local, regional, or distant relapse, or death due to any cause)